Literature DB >> 15196210

Insights into the regulation of immunoglobulin light chain gene rearrangements via analysis of the kappa light chain locus in lambda myeloma.

Vittorio Perfetti1, Maurizio C Vignarelli, Giovanni Palladini, Valentina Navazza, Claudia Giachino, Giampaolo Merlini.   

Abstract

Accumulating evidence indicates that B cells may undergo sequential rearrangements at the light chain loci, despite already expressing light chain receptors. This phenomenon may occur in the bone marrow and, perhaps, in germinal centers. As immunoglobulin (Ig)kappa light chains usually rearrange before Iglambda light chains, we analysed, by polymerase chain reaction, the Igkappa locus of bone marrow mononuclear cells from 29 patients with Iglambda myeloma to identify earlier recombinations in marrow plasma cells. The results demonstrated that Igkappa alleles were inactivated via the kappa-deleting element, presumably prior to V(kappa)-J(kappa) rearrangement, in many cases. Eighteen alleles (16 myeloma clones, 55%) showed V(kappa)-J(kappa) rearrangements, with increased utilization of 5' distant V(kappa) and 3' distant Jkappa gene segments (Jkappa4, 56%), an indication of multiple sequential rearrangements. In-frame, potentially functional V(kappa)-J(kappa) rearrangements were found in approximately one-third of available rearrangements (as expected by chance), each one in different myeloma clones: three were germline encoded, while one had several nucleotide substitutions, suggesting inactivation after the onset of somatic hypermutation. Three of four potentially functional V(kappa)-J(kappa)rearrangements involved V(kappa)4-1, a segment considered to be associated with autoimmunity. These findings provide insights into the regulation of light chain rearrangements and support the view that B cells may occasionally undergo sequential light chain rearrangements after the onset of somatic hypermutation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196210      PMCID: PMC1782513          DOI: 10.1046/j.1365-2567.2004.01902.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  54 in total

Review 1.  The mechanism and regulation of chromosomal V(D)J recombination.

Authors:  Craig H Bassing; Wojciech Swat; Frederick W Alt
Journal:  Cell       Date:  2002-04       Impact factor: 41.582

Review 2.  Role of receptor revision in forming a B cell repertoire.

Authors:  Jane Seagal; Doron Melamed
Journal:  Clin Immunol       Date:  2002-10       Impact factor: 3.969

3.  Receptor revision of immunoglobulin heavy chain genes in human MALT lymphomas.

Authors:  D Lenze; A Greiner; C Knörr; I Anagnostopoulos; H Stein; M Hummel
Journal:  Mol Pathol       Date:  2003-10

4.  Rapid expansion of human immunoglobulin repertoire (VH, V kappa, V lambda) expressed in early fetal bone marrow.

Authors:  A M Cuisinier; F Fumoux; D Moinier; L Boubli; V Guigou; M Milili; C Schiff; M Fougereau; C Tonnelle
Journal:  New Biol       Date:  1990-08

Review 5.  Light chains of immunoglobulins: structural-genetic correlates.

Authors:  A Solomon
Journal:  Blood       Date:  1986-09       Impact factor: 22.113

6.  Human immunoglobulin VH and VK repertoire revealed by in situ hybridization.

Authors:  V Guigou; A M Cuisinier; C Tonnelle; D Moinier; M Fougereau; F Fumoux
Journal:  Mol Immunol       Date:  1990-09       Impact factor: 4.407

7.  Increasing the thermostability of D-xylose isomerase by introduction of a proline into the turn of a random coil.

Authors:  G P Zhu; C Xu; M K Teng; L M Tao; X Y Zhu; C J Wu; J Hang; L W Niu; Y Z Wang
Journal:  Protein Eng       Date:  1999-08

8.  Indications for peripheral light-chain revision and somatic hypermutation without a functional B-cell receptor in precursors of a composite diffuse large B-cell and Hodgkin's lymphoma.

Authors:  Richard Rosenquist; Fabio Menestrina; Maurizio Lestani; Ralf Küppers; Martin-Leo Hansmann; Andreas Bräuninger
Journal:  Lab Invest       Date:  2004-02       Impact factor: 5.662

9.  Design of temperature-sensitive penicillinase repressors by replacement of Pro in predicted beta-turn structures.

Authors:  T Imanaka; M Nakae; T Ohta; M Takagi
Journal:  J Bacteriol       Date:  1992-02       Impact factor: 3.490

10.  A uniform deleting element mediates the loss of kappa genes in human B cells.

Authors:  K A Siminovitch; A Bakhshi; P Goldman; S J Korsmeyer
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

View more
  5 in total

Review 1.  Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Authors:  Even H Rustad; Eileen M Boyle
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-17       Impact factor: 3.020

2.  Molecular characterization of composite mantle cell and follicular lymphoma.

Authors:  Alberto Zamò; Roberta Zanotti; Maurizio Lestani; German Ott; Tiemo Katzenberger; Aldo Scarpa; Giovanni Pizzolo; Fabio Menestrina; Marco Chilosi
Journal:  Virchows Arch       Date:  2006-02-21       Impact factor: 4.064

3.  Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Authors:  Even H Rustad; Malin Hultcrantz; Venkata D Yellapantula; Theresia Akhlaghi; Caleb Ho; Maria E Arcila; Mikhail Roshal; Akshar Patel; Denise Chen; Sean M Devlin; Austin Jacobsen; Ying Huang; Jeffrey E Miller; Elli Papaemmanuil; Ola Landgren
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

4.  Development of a Phage Display Panning Strategy Utilizing Crude Antigens: Isolation of MERS-CoV Nucleoprotein human antibodies.

Authors:  Chia Chiu Lim; Patrick C Y Woo; Theam Soon Lim
Journal:  Sci Rep       Date:  2019-04-15       Impact factor: 4.379

5.  Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies.

Authors:  Won Sok Lee; Gurmukh Singh
Journal:  J Clin Med Res       Date:  2018-06-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.